# Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

> **NCT01297543** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cellerant Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemia
- Myelodysplasia

## Interventions

- **BIOLOGICAL:** human myeloid progenitor cells
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT01297543
- **Lead sponsor:** Cellerant Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2014-11
- **Final completion:** 2015-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01297543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01297543, "Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01297543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*